Seller record · Telehealth service

OrderlyMeds

Fails 1 of 8 criteria. S5, analytical documentation: The site asserts batch testing for sterility and potency, and no certificate of analysis, chromatogram or lot document is reachable from any page on the site.

At a glance

OrderlyMedsTelehealth service

7/8criteria passed
Price
GLP-1 $149 a month, GLP-1 plus GIP $299
Sells
compounded semaglutide, compounded tirzepatide, Wegovy, and 3 more
FDA letters
1 on file
Visit OrderlyMedsSee all eight dispositions

Telehealth service. Passes 7 of 8 criteria. Recorded against Standard v1.1.

A Georgia telehealth platform selling compounded semaglutide and tirzepatide alongside brand products. Its pages name several different sets of filling pharmacies, and an FDA warning letter names the operating entity.

Operating entity OrderlyMeds LLC

Dispositions

CodeCriterionDispositionWhere it appears
S1Prescriber requirementPASSOrderlyMeds' website
S2Prescription gatingPASSOrderlyMeds' eligibility page on its patient site
S3Pharmacy identificationPASSOrderlyMeds' FAQ
S4Compounding disclosurePASSOrderlyMeds' compounded GLP-1 product page
S5Analytical documentationFAILOrderlyMeds' website
S6Business addressPASSOrderlyMeds' terms and conditions
S7Price disclosurePASSOrderlyMeds' pricing page
S8Enforcement statusPASSFDA warning-letter index

Evidence, criterion by criterion

The evidence behind each disposition in the table above, where it appears, and its date.

S1PASSThe homepage states that a licensed physician reviews the health screening and holds a video visit where the state requires one, and a named Chief Medical Officer has a profile page.Source: OrderlyMeds' website.
S2PASSAn account-creation screen stops the order after an eligibility verdict, demanding a name, an email address and a telephone number.Source: OrderlyMeds' eligibility page on its patient site.
S3PASSThe frequently asked questions page names five filling pharmacies, PerfectRx/PerfectionRx, ProRx, Casa, Pharmacy Hub and SmartPharmaRx, with no address or state for any; other pages name different sets.Source: OrderlyMeds' FAQ.
S4PASSThe compounded product page carries the words compounded and not FDA-approved in visible text below the price block, repeated in the homepage price footnote.Source: OrderlyMeds' compounded GLP-1 product page.
S5FAILThe site asserts batch testing for sterility and potency, and no certificate of analysis, chromatogram or lot document is reachable from any page on the site.Source: OrderlyMeds' website.
S6PASSThe terms print a street address with a suite number and describe it as the company offices, repeated in the privacy policy.Source: OrderlyMeds' terms and conditions.
S7PASSThe pricing page prints 149 dollars per month for compounded GLP-1 injections and 299 dollars per month for compounded GLP-1 plus GIP, with brand plans at 1,839 dollars and 1,498 dollars.Source: OrderlyMeds' pricing page.
S8PASSFDA warning letter 728291, June 2026, names OrderlyMeds LLC and alleges misbranding; no FDA action has halted the business, and the seller still trades.Source: FDA warning-letter index.

Products shown on the seller's own pages at the recorded date: compounded semaglutide, compounded tirzepatide, Wegovy, Zepbound, NAD+, sermorelin.

Enforcement documents on file: 1 warning letter

FDA warning letter 728291, issued June 2026, to OrderlyMeds LLC dba OrderlyMedsA pictured label carries the OrderlyMeds logo, suggesting it is the compounder when it is not, and the site described its source as an FDA-licensed pharmacy, a designation FDA does not grant.

A warning letter alleges violations and requests a response. It does not halt a business, and it does not remove a seller from this ledger. Every letter recorded here.

Visit OrderlyMeds

Dispositions recorded against Standard v1.1. Method and null semantics: how checks are performed. This record is not a review and contains no medical advice.